Rhythm Pharmaceuticals' potential first-in-class HO drug, strong pipeline, and limited competition offer blockbuster potential. Click to read why RYTM is a Buy.

LSPN panellists from Mathys & Squire discuss recent developments affecting the EPO Boards of Appeal and decisions emerging ...